"Educational Intervention for Tokophobia in Pregnant Women" (TOKO-EDU)

November 5, 2026 updated by: Delta University for Science and Technology

Changes in Tokophobia Awareness, Fear of Childbirth, Coping Strategies, and Quality of Life Following Structured Educational Sessions Among Pregnant Women: A Quasi-Experimental Single-Group Pretest-Posttest Study

This quasi-experimental single-group pretest-posttest study examined immediate within-participant differences in tokophobia awareness, fear of childbirth, reported coping-strategy use, and quality of life among 50 pregnant women attending the antenatal outpatient clinics of Soad Kafafi Hospital, 6th of October City, Giza, Egypt.

Participants attended a standardized program comprising ten face-to-face sessions delivered twice weekly over five weeks. Each session lasted approximately 45-60 minutes, including orientation, baseline assessment, educational activities, review, and post-intervention evaluation.

Outcomes were assessed using the researcher-developed Tokophobia Awareness Questionnaire (TAQ), an Arabic translation of the Fear of Childbirth Questionnaire (FCQ), the Jalowiec Coping Scale (JCS), and WHOQOL-BREF. Baseline measures were completed before educational content was delivered. Post-intervention assessment took place immediately after the final session on the same day. No longer-term follow-up was conducted.

The absence of a comparison group prevents causal attribution of the observed differences to the educational sessions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study used a quasi-experimental single-group pretest-posttest design. Fifty pregnant women participated in the main study. Five separate women participated in pilot testing and were excluded from the main-study sample and analysis.

The main-study participants were divided into ten groups of five. The same educator, specializing in obstetric and gynecological health nursing, delivered the standardized program separately to each group. Other research-team members administered and collected the outcome questionnaires.

Each participant attended ten sessions over five consecutive weeks, with two sessions per week and approximately 45-60 minutes per session. Session 1 covered study orientation and procedures. Session 2 included baseline assessment, completed before delivery of educational content. Sessions 3-8 addressed tokophobia-related knowledge, childbirth preparation, coping strategies, stress management, communication, and professional and social support. Session 9 covered review and reinforcement. Session 10 included final reinforcement and immediate post-intervention assessment.

The TAQ assessed factual knowledge and awareness of tokophobia. The FCQ assessed self-reported fear of childbirth rather than establishing a clinical diagnosis of tokophobia. The JCS assessed frequency of coping-strategy use, and WHOQOL-BREF assessed self-reported quality of life across four domains.

No single primary outcome was prospectively designated. The continuous FCQ total score was prioritized for interpretation during manuscript revision. Analyses are exploratory because the study lacked a comparison group and multiple tests were conducted without adjustment.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Giza Governorate
      • Cairo, Giza Governorate, Egypt, 12566
        • Soad Kafafi Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Pregnant women aged 18 years or older.
  • Attending the antenatal outpatient clinics at the study setting.
  • Willing to participate and provide informed consent.

Exclusion Criteria:

- Diagnosed severe or acute psychiatric disorders that could interfere with study participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Educational Intervention Group

Pregnant women attended a standardized ten-session educational program delivered face-to-face in groups of five, twice weekly over five weeks. Each session lasted approximately 45-60 minutes, including orientation, assessment, educational activities, review, and evaluation. Educational content addressed tokophobia awareness, childbirth preparation, coping strategies, relaxation, stress management, and available professional and social support.

A structured educational program designed to provide information about tokophobia, its causes, symptoms, and management, along with training on psychological coping strategies and supportive techniques to enhance maternal well-being.

Other Names:
  • Tokophobia Education Program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Fear of Childbirth Questionnaire (FCQ) Total Score
Time Frame: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the 20-item FCQ total score from baseline to immediate post-intervention assessment. Items are scored 0-3, with positively worded items reverse-scored. Total scores range from 0 to 60; higher scores indicate greater fear of childbirth. The Arabic translation used in this study underwent preliminary linguistic and cultural adaptation.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Tokophobia Awareness Questionnaire (TAQ) Total Score
Time Frame: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the researcher-developed 23-item TAQ total score from baseline to immediate post-intervention assessment. Correct responses are scored 1 and incorrect responses 0. Total scores range from 0 to 23; higher scores indicate greater factual knowledge and awareness of tokophobia.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.
Change in Jalowiec Coping Scale (JCS) Total Score
Time Frame: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the 40-item JCS total score from baseline to immediate post-intervention assessment. Items are scored from 1 to 5, producing total scores ranging from 40 to 200. Higher scores indicate more frequent self-reported coping-strategy use.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.
Change in WHOQOL-BREF Domain Scores
Time Frame: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Changes from baseline to immediate post-intervention assessment in the four WHOQOL-BREF domains: physical health, psychological health, social relationships, and environment. Each domain score is transformed to a 0-100 scale, with higher scores indicating better self-reported quality of life. The four domains are analyzed separately.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Basma W Elrefay, phd, Delta University for Science and Technology, Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2025

Primary Completion (Actual)

May 10, 2025

Study Completion (Actual)

May 15, 2025

Study Registration Dates

First Submitted

April 4, 2026

First Submitted That Met QC Criteria

April 4, 2026

First Posted (Actual)

April 13, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DU-TOKO-2025-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be made publicly available due to privacy, confidentiality, and ethical restrictions related to the study participants.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.